



LATEST NEWS **OBAMA TO FOCUS ON ECONOMY IN HIGH-PROFILE SPEECH**

Quotes, News, Pictures & Video **SEARCH** Login



Top News
Reuters top ten news stories delivered to your inbox each day.
[Subscribe](#)

EUR/USD	
Sell	Buy
1.24	1.24
11	14
Low	High
1.2400	1.2490

The EURO is EASY to trade. See How [▶▶](#)
Forex trading involves significant risk of loss and may not be suitable for all investors.

FREE PRACTICE ACCOUNT
[CLICK HERE](#)

FXCM
24 Hour Online Currency Trading

You are here: [Home](#) > [News](#) > [Article](#)

DJIA : **7360.57** ▲ | Nasdaq : **1440.69** ▲

Authority on Adult Stem Cell Therapy Astounds Over 200 Physicians at Anti-Aging Conference in Nation's Capital

Sat Jul 19, 2008 12:07pm EDT

[Email](#) | [Print](#) | [Share](#) | [Reprints](#) | [Single Page](#)

[\[-\] Text \[+\]](#)

EDITOR'S CHOICE



A selection of our best photos from the past 24 hours. [Slideshow](#)

FXCM Trading Accounts

FXCM Micro FXCM Platform Active Trader

Rollover the tabs to learn more.

EUR/USD 1.4591/93

Volatility:

Volume:

Range:

No Trades

Breakout

Momentum

Momentum1

Momentum2

Trend

80

81

FXCM

Online Currency Trading

CURRENCY TRADING INVOLVES SIGNIFICANT RISK OF LOSS.

MOST POPULAR ON REUTERS

[Articles](#) | [Video](#)

1. **AIG in talks with U.S. government, sees \$60 billion loss: source** | [source](#) | [Video](#)
2. U.S. home prices drop at record pace in December: S&P
3. Soros sees no bottom for world financial "collapse" | [Video](#)
4. Stanford had links to fund run by Bidens: report
5. U.S. home prices, German morale wilt
6. Q+A: Why would North Korea test-fire its missiles?
7. Russian general says watching Arctic militarization
8. Microsoft says no new cost cuts, shares hit 11-year low
9. AmEx paying card holders to close their accounts | [Video](#)
10. "Milk" loses best film, but sparks new activism | [Video](#)

[Most Popular Articles RSS Feed](#)

Reuters Deals

The global destination for corporate leaders, deal-makers and innovators

[Knowledge to Act](#)



Reuters.com: [Help and Contact Us](#) | [Advertise With Us](#) | [Mobile](#) | [Newsletters](#) | [RSS](#) | [Interactive TV](#) | [Labs](#) | [Reuters in Second Life](#) | [Archive](#) | [Site Index](#) | [Video Index](#)

Thomson Reuters Corporate: [Copyright](#) | [Disclaimer](#) | [Privacy](#) | [Professional Products](#) | [Professional Products Support](#) | [About Thomson Reuters](#) | [Careers](#)

International Editions: [Africa](#) | [Arabic](#) | [Argentina](#) | [Brazil](#) | [Canada](#) | [China](#) | [France](#) | [Germany](#) | [India](#) | [Italy](#) | [Japan](#) | [Latin America](#) | [Mexico](#) | [Russia](#) | [Spain](#) | [United Kingdom](#) | [United States](#)

Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.

WASHINGTON, DC, Jul 19 (MARKET WIRE) --

Speaking at the 16th Annual World Congress on Anti-Aging Medicine & Regenerative Biomedical Technologies at the Gaylord National Resort in Washington, DC, on Friday, July 18, Florida-based cardiologist Dr. Zannos Grekos astounded over 200 physicians with a presentation on the impressive regenerative behavior of pre-engineered adult stem cells injected into patients with cardiomyopathy. The presentation by the lead cardiologist of Regenocyte(TM) Therapeutic (www.regenocyte.com) included a report on the company's post-stem cell treatment results citing an average increase of 21 percent in cardiac ejection rates as well as measurable improvements in a patient's congestive heart failure class status.

"We're able to bring a patient from a Class IV status to a Class II status in less than 180 days," said Grekos commenting on the success rate of Regenocyte patients receiving adult stem cell therapy to repair damage to heart muscle and arteries caused by atherosclerosis, a disease that causes heart muscle disorders and infarction due to plaque formation in the cardiac arteries in over 500,000 Americans.

According to the Congestive Heart Failure (CHF) Classification System by the New York Heart Association, patients suffering from CHF are categorized into four classes based on the disease's degree of severity. Patients in the lowest classification, Class IV, experience increased pulmonary edema, severe shortness of breath, and can be dependent on an implanted defibrillator and/or continuous infusion of Milrinone, a cardiac drug that improves blood flow by chemically increasing a patient's ejection fraction or ventricular blood pumping rate.

"I've seen patients go from an ejection fraction of 28 percent to 49 percent in six months with the stem cell therapy," he told the captive audience. (An ejection fraction of 50 is normal.) "Injecting a patient's own stem cells into damaged tissue is replacing damaged cells with normal functioning cells. At this point, the patient can discontinue Milrinone infusions and potentially the need of an implanted defibrillator."

Immediately following the presentation, over two-dozen physicians insisting on discovering more about his work approached Grekos in the hallway outside the auditorium. The group was particularly fascinated with the center's research proving that adult stem cells have the ability to engraft themselves into areas damaged by myocardial infarction (heart attacks) and turn into new heart cells and new blood vessels.

Dr. Grekos responded to the forum by stating, "Three months after treatment, cardiac nuclear scans of the areas treated reveal reversal of damage. In some cases, it's virtually impossible to identify the problems that existed before therapy. We have shown such improvement in some patients that they were taken off the heart transplant list."

In adult stem cell therapy, a patient's stem cells are extracted through a simple blood draw at the Regenocyte Clinical Center in Florida. The sample is sent to a biotechnology laboratory in Israel where the cells are cultivated and pre-engineered into millions of cardiac regenocytes (living heart repair cells). The patient receives injections of the new cells one week later at one of the clinic's internationally licensed treatment centers. Over the next few months, the cells stimulate tissue re-growth and create greater blood flow to the affected areas. Unlike surgically implanted devices, medications, or organ replacement surgery, using a patient's own stem cells to rebuild damaged heart muscles means there is no possibility of rejection or tumorigenicity (cancer causing).

Dr. Grekos and his colleagues in the world medical field are currently employing adult stem cell therapy and coordinating its application for thousands of American patients who have exhausted all other traditional therapy options. His presentation at the 16th Annual World Congress on Anti-Aging Medicine & Regenerative Biomedical Technologies conference supports efforts by a global community of doctors that are striving to incorporate adult stem cell therapy into mainstream medicine.

Dr. Zannos Grekos will be hosting several public seminars in Naples, Florida and Hilton Head, South Carolina in August 2008. He will also be a featured lecturer at another World Congress on Anti-Aging Medicine & Regenerative Biomedical Technologies conference in Las Vegas on December 11-14, 2008.

Regenocyte(TM) Therapeutic is an international corporation located in Bonita Springs, Florida. Dedicated to leading the world in providing Adult Stem Cell therapies, Regenocyte(TM) Therapeutic utilizes the most effective and safest technologies and medical procedures in order to prolong and improve the lives of its patients. A video of Dr. Grekos' presentation at the 16th Annual World Congress on Anti-Aging Medicine & Regenerative Biomedical Technologies will be available for viewing on the company's website by August 1st. Additional information on adult stem cell therapy as well as patient video testimonials, and seminar reservation requests can be found at www.regenocyte.com.

Copyright 2008, Market Wire, All rights reserved.

-0-

© Thomson Reuters 2009 All rights reserved

SHARE: [Del.icio.us](#) [Digg](#) [Mixx](#) [My Web](#) [Facebook](#) [LinkedIn](#)

ALSO ON REUTERS



Q+A: Why would North Korea test-fire its missiles?



Video: Israel apologizes for Jesus spoof



Health spending takes rising share of U.S. economy

MORE PRESS RELEASE

- [Financial Federal Corporation Second Quarter Fiscal 2009 Earnings Release and Conference Call Notice](#)
- [Evertz Technologies Limited to Announce Third Quarter 2009 Results on March 10, 2009](#)
- [20 Electronics Industry Leaders Collaborate to Accelerate Development and Adoption...](#)
- [dav Rainwear Makes Red Carpet Splash Coast to Coast](#)
- [Evertz Technologies Limited to Announce Third Quarter 2009 Results on March 10, 2009](#)
- [More Press Release News...](#)

Ads by Google [What's This?](#)

#1 Wrinkle Cream Winner
Over 500 Creams Tested and Reviewed Find Out Who Won The Award For 2009
[SkinCreamTrial.com/Winner](#)

New Stem Cell Treatment
High standard German clinic treats degenerative diseases. Request info
[www.XCell-Center.com/StemCells/](#)

Anti-Aging Hormone MDs
South Florida Physicians specialize in Natural Bioidentical Hormones.
[www.BodyLogicMD.com](#)

End-stage heart failure
Left ventricular assist device may increase survival in some patients.
[www.hearthope.com](#)

Reuters.com: [Help and Contact Us](#) | [Advertise With Us](#) | [Mobile](#) | [Newsletters](#) | [RSS](#) | [Interactive TV](#) | [Labs](#) | [Reuters in Second Life](#) | [Archive](#) | [Site Index](#) | [Video Index](#)

Thomson Reuters Corporate: [Copyright](#) | [Disclaimer](#) | [Privacy](#) | [Professional Products](#) | [Professional Products Support](#) | [About Thomson Reuters](#) | [Careers](#)

International Editions: [Africa](#) | [Arabic](#) | [Argentina](#) | [Brazil](#) | [Canada](#) | [China](#) | [France](#) | [Germany](#) | [India](#) | [Italy](#) | [Japan](#) | [Latin America](#) | [Mexico](#) | [Russia](#) | [Spain](#) | [United Kingdom](#) | [United States](#)

Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.

NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please [click here](#).